A Phase II International, Multicenter Study of Oral Panobinostat (LBH589) in Patients With Refractory Cutaneous T-Cell Lymphoma. Hematol Meeting Rep 2009, 2 (5). https://doi.org/10.4081/hmr.v2i5.725.